After three losing days, Canada’s main stock index rose on Thursday led by mining and energy growth while losses in the healthcare segment capped further gains on the TSX. With plenty of domestic earnings updates, traders were cautious ahead of a key U.S. inflation print. Statistics Canada reported real gross domestic product was essentially unchanged in December 2023 after two months of growth. Asian markets were down while Euro markets ended higher.

U.S. indexes were mostly unchanged as Wall Street weighed the latest earnings results and looked ahead to the Federal Reserve’s favoured inflation gauge. The personal consumer expenditures reading for January 2024, which came in higher than expected and could impact equities in the future.

TSX21,363.61+119.84TSX
TSXV560.11+5.52TSXV
CSE184.49-0.25CSE
DJIA38,996.39+47.37DJIA
NASDAQ16,091.92+144.18NASDAQ
S&P 5005,098.04+28.28S&P 500

The Canadian dollar traded for 73.66 cents compared with 73.67 cents U.S. on Wednesday.

U.S. crude futures traded $0.44 lower at $78.10 a barrel, and the Brent contract lost $0.06 to $83.62 a barrel.

The price of gold was up US$9.56 to US$2,044.24.

In world markets, the Nikkei was down 41.84 points to 39,166.19, the Hang Seng was down 25.41 points to 16,511.44, the FTSE was up 24.59 points to 7,649.57, and the DAX was up 105.68 points to 17,706.90.


The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online
An AI generated photo of a stethoscope on a computerized setting

How one company is disrupting PoC testing

When it comes to Gemina Laboratories Ltd. (CSE:GLAB), the Canada and U.K.-based company is progressing a range of PoC diagnostic technologies.
Bear and bull statues wearing Christmas hats

@ the Bell: TSX advances to start off Christmas trading week

Canada’s TSX index closed higher on Monday thanks to large-cap gains, despite weakness in real estate and telecom stocks.
Doctor with a bladder replica

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient’s Guide

As a patient with BCG-Unresponsive NMIBC CIS, bladder removal is far from the only option on the table in 2024.
Nervous system

NervGen Pharma: Proof that NVG-291 works?

Tantalizing anecdotal “evidence” has just been published suggesting that NervGen’s prospective wonder-drug, NVG-291, is delivering the goods.